DK1771178T3 - Anvendelse af K-252A og kinaseinhibitorer til forebyggelse eller behandling af HMGB1-assocuerede patologiske tilstande - Google Patents

Anvendelse af K-252A og kinaseinhibitorer til forebyggelse eller behandling af HMGB1-assocuerede patologiske tilstande

Info

Publication number
DK1771178T3
DK1771178T3 DK05778429T DK05778429T DK1771178T3 DK 1771178 T3 DK1771178 T3 DK 1771178T3 DK 05778429 T DK05778429 T DK 05778429T DK 05778429 T DK05778429 T DK 05778429T DK 1771178 T3 DK1771178 T3 DK 1771178T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
hmgb1
kinase inhibitors
pathological conditions
Prior art date
Application number
DK05778429T
Other languages
English (en)
Inventor
Silvano Fumero
Francesco P Pilato
Domenico Barone
Rava Rossa Luisa Bertarione
Valentina Mainero
Silvio Traversa
Original Assignee
Creabilis Therapeutics Spa
Bio3Res Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creabilis Therapeutics Spa, Bio3Res Srl filed Critical Creabilis Therapeutics Spa
Application granted granted Critical
Publication of DK1771178T3 publication Critical patent/DK1771178T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05778429T 2004-07-29 2005-07-29 Anvendelse af K-252A og kinaseinhibitorer til forebyggelse eller behandling af HMGB1-assocuerede patologiske tilstande DK1771178T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59188004P 2004-07-29 2004-07-29
US64700705P 2005-01-27 2005-01-27
PCT/EP2005/008258 WO2006010628A1 (en) 2004-07-29 2005-07-29 Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies

Publications (1)

Publication Number Publication Date
DK1771178T3 true DK1771178T3 (da) 2009-11-02

Family

ID=35262096

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05778429T DK1771178T3 (da) 2004-07-29 2005-07-29 Anvendelse af K-252A og kinaseinhibitorer til forebyggelse eller behandling af HMGB1-assocuerede patologiske tilstande

Country Status (14)

Country Link
US (1) US20090191253A2 (da)
EP (1) EP1771178B1 (da)
JP (1) JP2008508220A (da)
AT (1) ATE438404T1 (da)
AU (1) AU2005266447A1 (da)
CA (1) CA2575272A1 (da)
DE (1) DE602005015862D1 (da)
DK (1) DK1771178T3 (da)
ES (1) ES2327659T3 (da)
MX (1) MX2007001155A (da)
PL (1) PL1771178T3 (da)
PT (1) PT1771178E (da)
SI (1) SI1771178T1 (da)
WO (1) WO2006010628A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006298858A (ja) * 2005-04-22 2006-11-02 Yamaguchi Univ 細胞内寄生性微生物に対し新規抑制効果を有するアポトーシス誘導剤
SI1919979T2 (sl) 2005-08-25 2017-07-31 Creabilis Therapeutics S.P.A. Polimerni konjugati K-252A in njihovi derivati
EP1931424A2 (en) * 2005-09-07 2008-06-18 Laboratoires Serono S.A. P13k inhibitors for the treatment of endometriosis
AU2009240884B8 (en) 2008-04-30 2014-03-06 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
CN102083962B (zh) 2008-04-30 2013-03-27 吉诺米克斯股份有限公司 生物体内功能性细胞的高效采集方法
WO2010034779A2 (en) * 2008-09-24 2010-04-01 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Composition and method for treatment of preterm labor
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US20100267742A1 (en) * 2009-04-17 2010-10-21 Rush University Medical Center Combination targeted therapy for lung cancer
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
WO2011052668A1 (ja) 2009-10-28 2011-05-05 株式会社ジェノミックス 骨髄間葉系および/または多能性幹細胞の血中動員による組織再生促進剤
ES2413437T3 (es) * 2010-03-10 2013-07-16 Institut Pasteur HMGB1 y anticuerpos anti-HMGB1 en pacientes infectados por VIH especialmente con trastornos neurológicos
PT2703487T (pt) 2011-04-26 2018-10-11 Genomix Co Ltd Péptido para induzir a regeneração de um tecido e a sua utilização
FI20115640A0 (fi) 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2014009609A1 (en) 2012-07-13 2014-01-16 Turun Yliopisto Combination therapy iii
JP6253590B2 (ja) 2012-10-25 2017-12-27 株式会社ジェノミックス Ｈｍｇｂ１断片を利用した脊髄の損傷に対する新規治療法
JP6253589B2 (ja) 2012-10-25 2017-12-27 株式会社ジェノミックス Ｈｍｇｂ１断片を利用した新規心筋梗塞の治療法
JP2014162752A (ja) * 2013-02-25 2014-09-08 Dic Corp 化合物、液晶組成物、及び表示装置
JP2014162751A (ja) * 2013-02-25 2014-09-08 Dic Corp 化合物、液晶組成物、及び表示装置
JP6513795B2 (ja) * 2014-09-12 2019-05-15 ザ プロクター アンド ギャンブル カンパニー スキンケア組成物の製造方法
US20200039922A1 (en) * 2016-10-05 2020-02-06 Afecta Pharmaceuticals, Inc. High mobility group b1 protein inhibitors
KR102559262B1 (ko) 2017-01-27 2023-07-25 가부시키가이샤 스템림 심근증, 진구성 심근경색 및 만성심부전의 치료약
TWI645083B (zh) * 2017-08-30 2018-12-21 金立德 篩選抑制發炎反應及血管保護活性物質之方法
EP3718561A4 (en) 2017-12-01 2021-07-21 Stemrim Inc. Therapy for inflammatory bowel disease
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
CN112176066B (zh) * 2020-10-30 2022-07-01 中国科学院合肥物质科学研究院 一种宫颈病变早期筛查和诊断的分子标志物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) * 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0699311B2 (ja) * 1986-11-06 1994-12-07 旭化成工業株式会社 抗血管レン縮剤および血管弛緩剤
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5633235A (en) * 1991-04-19 1997-05-27 Regents Of The University Of Michigan Triciribine and analogs as antiviral drugs
EP0541486A1 (de) * 1991-11-07 1993-05-12 Ciba-Geigy Ag Polycyclische Konjugate
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5441947A (en) * 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
JPH07223958A (ja) * 1994-02-14 1995-08-22 Asahi Chem Ind Co Ltd 血管肥厚抑制剤
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
EP0711557A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733358A3 (de) * 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
US5977184A (en) * 1995-09-15 1999-11-02 Thorne Research, Inc. Quercetin chalcone and methods related thereto
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
NZ333441A (en) * 1996-06-25 1999-05-28 Cephalon Inc Use of k-252a derivatives for the treatment of peripheral or central nerve disorders, and cytokine overproduction
EP1003519A4 (en) * 1997-03-03 2003-08-20 Univ Texas SUPPRESSION OF CYCLINKINASE-2 ACTIVITY FOR PREVENTION AND THERAPY OF DNA VIRAL INFECTIONS
US6025365A (en) * 1997-03-25 2000-02-15 Arch Development Corp. Chelerythrine and radiation combined tumor therapy
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
CA2333661A1 (en) * 1998-05-29 1999-12-09 Cnrs (Centre National De Recherche Scientifique) France Innovation Scien Tifique Et Transfernt Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
WO2000021531A1 (fr) * 1998-10-13 2000-04-20 Kyowa Hakko Kogyo Co., Ltd. Medicaments pour maladies oculaires
BR9915569A (pt) * 1998-11-23 2001-08-14 Novartis Ag Método para o tratamento de doenças neovasculares oculares
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
NZ517578A (en) * 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
US20010025059A1 (en) * 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US7419678B2 (en) * 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
JP2004517631A (ja) * 2001-01-17 2004-06-17 ヨウン メー パク クエルセチンにより血管内皮成長因子及びエリスロポエチンの遺伝子発現を阻害する方法
WO2002074242A2 (en) * 2001-03-16 2002-09-26 Tyler Curiel Inhibition of toxoplasma gondii) replication by pyridinylimidazoles
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
NZ532593A (en) * 2001-10-25 2007-11-30 Wisconsin Alumni Res Found Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
AU2003222221A1 (en) * 2002-02-15 2004-10-25 The General Hospital Corporation Map-kinase inhibitors as regulators of tumour-associated antigen expression
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7232906B2 (en) * 2002-06-05 2007-06-19 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
AU2003279795A1 (en) * 2002-10-04 2004-05-04 Caritas St.Elisabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization
EP1413887A1 (en) * 2002-10-22 2004-04-28 Aventis Pharma S.A. Inhibitors of Src kinase for use in Alzheimer's disease
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005014003A1 (en) * 2003-07-23 2005-02-17 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation
WO2005074921A1 (en) * 2004-02-09 2005-08-18 University Of Zurich Treatment of atherosclerosis

Also Published As

Publication number Publication date
ES2327659T3 (es) 2009-11-02
DE602005015862D1 (de) 2009-09-17
EP1771178B1 (en) 2009-08-05
JP2008508220A (ja) 2008-03-21
SI1771178T1 (sl) 2010-01-29
ATE438404T1 (de) 2009-08-15
CA2575272A1 (en) 2006-02-02
MX2007001155A (es) 2007-08-14
US20090191253A2 (en) 2009-07-30
PL1771178T3 (pl) 2010-01-29
US20080317809A1 (en) 2008-12-25
EP1771178A1 (en) 2007-04-11
WO2006010628A1 (en) 2006-02-02
AU2005266447A1 (en) 2006-02-02
PT1771178E (pt) 2009-11-12

Similar Documents

Publication Publication Date Title
DK1771178T3 (da) Anvendelse af K-252A og kinaseinhibitorer til forebyggelse eller behandling af HMGB1-assocuerede patologiske tilstande
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20081454L (no) Met-kinaseinhibitorer
BRPI0608886B8 (pt) derivados de n-sulfonilpirróis e seus usos
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NO20082793L (no) Nye tiofenderivater
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA200801199A1 (ru) Ингибиторы киназы
EA201391705A1 (ru) Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
ATE483000T1 (de) Naphtalin-amidin-imide
NO20090764L (no) 4-hydroksytiobenzamidderivater og legemidler
ATE510822T1 (de) Kaliumkanalinhibitoren
NO20082096L (no) Azaindol-2-karboksamidderivativer
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler